ANI Pharmaceuticals (ANIP) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 net revenues of $148.3M, up 12.5% year-over-year, driven by strong growth in rare disease and generics segments, and completed the transformative acquisition of Alimera Sciences, adding ILUVIEN and YUTIQ to the rare disease portfolio and expanding international presence.

• Integration of Alimera progressing well, with a 45-person ophthalmology sales force now promoting Cortropin Gel, ILUVIEN, and YUTIQ.

• Rare disease business, led by Cortropin Gel, is expected to become the largest business unit and primary growth driver in 2025.

• Implemented a new capital structure expected to reduce annualized interest expense by $39M.

• Sale of Oakville, Ontario facility completed in March 2024, resulting in a $5.3M gain.

Financial highlights

• Q3 2024 total/net revenues reached $148.3M, up 12.5% year-over-year; nine months ended net revenues: $423.8M (+19.3% YoY).

• Cortropin Gel revenues were $52.6M, up 77% year-over-year; rare disease segment Q3 revenues: $56.4M (+89.8% YoY); generics revenues were $78.2M, up 11% year-over-year.

• Q3 2024 net loss of $(24.2)M; adjusted non-GAAP EBITDA was $35.1M; adjusted non-GAAP EPS was $1.34.

• Gross margin decreased to 57.5% GAAP (from 63.5%) and 59.9% non-GAAP (from 63.7%) year-over-year.

• Ended Q3 with $145M in cash and $641.3M in outstanding debt.

Outlook and guidance

• Raised full-year 2024 net revenue guidance to $594–$602M (22–24% growth year-over-year); adjusted non-GAAP EBITDA $149–$153M; adjusted non-GAAP EPS $4.90–$5.05.

• Cortropin Gel revenue guidance increased to $196–$200M (75–78% growth year-over-year).

• ILUVIEN and YUTIQ expected to contribute $30–$32M for the post-close period in 2024.

• Adjusted non-GAAP gross margin expected at the high end of 61–62%.

• Anticipates high single-digit to low double-digit accretion in 2025 adjusted non-GAAP EPS from Alimera acquisition.